Copy number variability analysis of pharmacogenes in patients with lymphoma, leukemia, hepatocellular, and lung carcinoma using the Cancer Genome Atlas data

Pharmacogenetics and Genomics

Volumn 25, Issue 1, 2015, Pages 1-7

  Kim, In Wha ^a   Han, Nayoung ^a   Kim, Myeong Gyu ^a   Kim, Therasa ^b   Oh, Jung Mi ^a  

^a Seoul National University   (South Korea)

^b Chonnam National University   (South Korea)

Author keywords

Copy number variation; Multiple cancers; Pharmacogenomics

Indexed keywords

CONCENTRATIVE NUCLEOSIDE TRANSPORTER 1; CYTOCHROME P450 2A6; CYTOCHROME P450 2D6; CYTOCHROME P450 2E1; DRUG METABOLIZING ENZYME; FRAGILE HISTIDINE TRIAD PROTEIN; GLUTATHIONE TRANSFERASE M1; GLUTATHIONE TRANSFERASE P1; GLUTATHIONE TRANSFERASE T1; MULTIDRUG RESISTANCE PROTEIN 1; PURINERGIC P2Y1 RECEPTOR; PURINERGIC P2Y12 RECEPTOR; REDUCED FOLATE CARRIER; SULFOTRANSFERASE 1A1; PHARMACOLOGICAL BIOMARKER; TUMOR PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; BLOOD ANALYSIS; CANCER TISSUE; COPY NUMBER VARIATION; GENE AMPLIFICATION; GENE EXPRESSION; GENE FREQUENCY; GENE LOSS; GENE TARGETING; GENETIC ANALYSIS; GENETIC VARIABILITY; GERM LINE; HUMAN; LARGE CELL LYMPHOMA; LIVER CELL CARCINOMA; LUNG SQUAMOUS CELL CARCINOMA; PHARMACEUTICAL CARE; PHARMACOGENETICS; PHARMACOGENOMICS; PREVALENCE; CARCINOMA, HEPATOCELLULAR; DRUG INACTIVATION; GENETIC PREDISPOSITION; GENETICS; GERM CELL; HUMAN GENOME; LEUKEMIA; LIVER NEOPLASMS; LUNG NEOPLASMS; LYMPHOMA;

BIOMARKERS, PHARMACOLOGICAL; CARCINOMA, HEPATOCELLULAR; DNA COPY NUMBER VARIATIONS; GENETIC PREDISPOSITION TO DISEASE; GENOME, HUMAN; GERM CELLS; HUMANS; INACTIVATION, METABOLIC; LEUKEMIA; LIVER NEOPLASMS; LUNG NEOPLASMS; LYMPHOMA; NEOPLASM PROTEINS; PHARMACOGENETICS;

EID: 84918575747     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0000000000000097     Document Type: Article

References (45)

1. Eichelbaum M, Ingelman-Sundberg M, Evans WE. Pharmacogenomics and individualized drug therapy. Annu Rev Med 2006; 57:119-137.
2. Evans WE, McLeod HL. Pharmacogenomics - drug disposition, drug targets, and side effects. N Engl J Med 2003; 348:538-549.
3. Evans WE, Relling MV. Pharmacogenomics: translating functional genomics into rational therapeutics. Science 1999; 286:487-491.
4. Lu AY. Drug-metabolism research challenges in the new millennium: individual variability in drug therapy and drug safety. Drug Metab Dispos 1998; 26:1217-1222.
5. Meyer UA. Pharmacogenetics and adverse drug reactions. Lancet 2000; 356:1667-1671.
6. McCarroll SA, Hadnott TN, Perry GH, Sabeti PC, Zody MC, Barrett JC, et al. International HapMap Consortium. Common deletion polymorphisms in the human genome. Nat Genet 2006; 38:86-92.
7. Schoumans J, Ruivenkamp C, Holmberg E, Kyllerman M, Anderlid BM, Nordenskjöld M. Detection of chromosomal imbalances in children with idiopathic mental retardation by array based comparative genomic hybridisation (array-CGH). J Med Genet 2005; 42:699-705.
8. Craddock N, Hurles ME, Cardin N, Pearson RD, Plagnol V, Robson S, et al. Wellcome Trust Case Control Consortium. Genome-wide association study of CNVs in 16,000 cases of eight common diseases and 3,000 shared controls. Nature 2010; 464:713-720.
9. Johansson I, Ingelman-Sundberg M. CNVs of human genes and their implication in pharmacogenetics. Cytogenet Genome Res 2008; 123:195-204.
10. Redon R, Ishikawa S, Fitch KR, Feuk L, Perry GH, Andrews TD, et al. Global variation in copy number in the human genome. Nature 2006; 444:444-454.
11. Piotrowski A, Bruder CE, Andersson R, Diaz de Ståhl T, Menzel U, Sandgren J, et al. Somatic mosaicism for copy number variation in differentiated human tissues. Hum Mutat 2008; 29:1118-1124.
12. Lupski JR, Stankiewicz P. Genomic disorders: molecular mechanisms for rearrangements and conveyed phenotypes. PLoS Genet 2005; 1:e49.
13. Hastings PJ, Lupski JR, Rosenberg SM, Ira G. Mechanisms of change in gene copy number. Nat Rev Genet 2009; 10:551-564.
14. Gaedigk A, Twist GP, Leeder JS. CYP2D6, SULT1A1 and UGT2B17 copy number variation: quantitative detection by multiplex PCR. Pharmacogenomics 2012; 13:91-111.
15. Hebbring SJ, Adjei AA, Baer JL, Jenkins GD, Zhang J, Cunningham JM, et al. Human SULT1A1 gene: copy number differences and functional implications. Hum Mol Genet 2007; 16:463-470.
16. Huang RS, Chen P, Wisel S, Duan S, Zhang W, Cook EH, et al. Populationspecific GSTM1 copy number variation. Hum Mol Genet 2009; 18:366-372.
17. Gaedigk A. Complexities of CYP2D6 gene analysis and interpretation. Int Rev Psychiatry 2013; 25:534-553.
18. Ingelman-Sundberg M. Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity. Pharmacogenomics J 2005; 5:6-13.
19. He Y, Hoskins JM, McLeod HL. Copy number variants in pharmacogenetic genes. Trends Mol Med 2011; 17:244-251.
20. Scherer SW, Lee C, Birney E, Altshuler DM, Eichler EE, Carter NP, et al. Challenges and standards in integrating surveys of structural variation. Nat Genet 2007; 39 (Suppl):S7-S15.
21. Weinstein JN, Collisson EA, Mills GB, Shaw KR, Ozenberger BA, Ellrott K, et al. Cancer Genome Atlas Research Network. The Cancer Genome Atlas Pan-Cancer analysis project. Nat Genet 2013; 45:1113-1120.
22. Hertz DL, McLeod HL. Use of pharmacogenetics for predicting cancer prognosis and treatment exposure, response and toxicity. J Hum Genet 2013; 58:346-352.
23. The Cancer Genome Atlas Program Office. The Cancer Genome Atlas. Available at: http://cancergenome.nih.gov/. [Accessed 1 August 2014].
24. Pharmacogenomics and bioinformatics: PharmGKB. The Pharmacogenomics Knowledgebase. Available at: https://www.pharmgkb. org/. [6 Accessed July 2014].
25. Whirl-Carrillo M, McDonagh EM, Hebert JM, Gong L, Sangkuhl K, Thorn CF, et al. Pharmacogenomics knowledge for personalized medicine. Clin Pharmacol Ther 2012; 92:414-417.
26. US Food and Drug Administration. Table of Pharmacogenomic Biomarkers in Drug Labels. Available at: http://www.fda.gov/Drugs/ScienceResearch/ ResearchAreas/Pharmacogenetics/ucm083378.htm. [Accessed 6 December 2013].
27. National Center for Biotechnology Information (US). Pubmed.gov. Available at: http://www.ncbi.nlm.nih.gov/pubmed. [Accessed 6 December 2013].
28. Brennan C, Momota H, Hambardzumyan D, Ozawa T, Tandon A, Pedraza A, Holland E. Glioblastoma subclasses can be defined by activity among signal transduction pathways and associated genomic alterations. PLoS One 2009; 4:e7752.
29. Computational Biology Center at Memorial Sloan-Kettering Cancer Center and the i-Vis (Information Visualization) Research Group of the Computer Engineering Department at Bilkent University. cBioPortal for Cancer Genomics. Available at: http://www.cbioportal.org/public-portal/index.do. [Accessed 6 December 2013].
30. Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov 2012; 2:401-404.
31. Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal 2013; 6:pl1.
32. Mermel CH, Schumacher SE, Hill B, Meyerson ML, Beroukhim R, Getz G. GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. Genome Biol 2011; 12:R41.
33. Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res 2003; 13:2498-2504.
34. Piacentini S, Polimanti R, Porreca F, Martínez-Labarga C, De Stefano GF, Fuciarelli M. GSTT1 and GSTM1 gene polymorphisms in European and African populations. Mol Biol Rep 2011; 38:1225-1230.
35. Martis S, Mei H, Vijzelaar R, Edelmann L, Desnick RJ, Scott SA. Multi-ethnic cytochrome-P450 copy number profiling: novel pharmacogenetic alleles and mechanism of copy number variation formation. Pharmacogenomics J 2013; 13:558-566.
36. Niedzielska E, Weclawek-Tompol J, Matkowska-Kocjan A, Chybicka A. The influence of genetic RFC1, MS and MTHFR polymorphisms on the risk of acute lymphoblastic leukemia relapse in children and the adverse effects of methotrexate. Adv Clin Exp Med 2013; 22:579-584.
37. Pastor-Anglada M, Cano-Soldado P, Errasti-Murugarren E, Casado FJ. SLC28 genes and concentrative nucleoside transporter (CNT) proteins. Xenobiotica 2008; 38 (7-8):972-994.
38. Saldivar JC, Shibata H, Huebner K. Pathology and biology associated with the fragile FHIT gene and gene product. J Cell Biochem 2010; 109:858-865.
39. Chang NS, Hsu LJ, Lin YS, Lai FJ, Sheu HM. WW domain-containing oxidoreductase: a candidate tumor suppressor. Trends Mol Med 2007; 13:12-22.
40. Gebhart E. Comparative genomic hybridization (CGH): ten years of substantial progress in human solid tumor molecular cytogenetics. Cytogenet Genome Res 2004; 104:352-358.
41. Dean M. ABC transporters, drug resistance, and cancer stem cells. J Mammary Gland Biol Neoplasia 2009; 14:3-9.
42. Matherly LH, Hou Z, Deng Y. Human reduced folate carrier: translation of basic biology to cancer etiology and therapy. Cancer Metastasis Rev 2007; 26:111-128.
43. Gupta S,Wulf G, Henjakovic M, Koepsell H, Burckhardt G, Hagos Y. Human organic cation transporter 1 is expressed in lymphoma cells and increases susceptibility to irinotecan and paclitaxel. J Pharmacol Exp Ther 2012; 341:16-23.
44. Johnson JA. Pharmacogenetics in clinical practice: how far have we come and where are we going? Pharmacogenomics 2013; 14:835-843.
45. Sekine I, Yamamoto N, Nishio K, Saijo N. Emerging ethnic differences in lung cancer therapy. Br J Cancer 2008; 99:1757-1762.